BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33791882)

  • 21. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection.
    Zhu X; Wang LC; Chen EQ; Chen XB; Chen LY; Liu L; Lei XZ; Liu C; Tang H
    Dig Dis Sci; 2011 Sep; 56(9):2742-9. PubMed ID: 21399926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    Kim WR; Berg T; Asselah T; Flisiak R; Fung S; Gordon SC; Janssen HL; Lampertico P; Lau D; Bornstein JD; Schall RE; Dinh P; Yee LJ; Martins EB; Lim SG; Loomba R; Petersen J; Buti M; Marcellin P
    J Hepatol; 2016 Apr; 64(4):773-80. PubMed ID: 26626497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers].
    Zhang XY; Qian J; Li P; Hu LH; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):332-336. PubMed ID: 29996199
    [No Abstract]   [Full Text] [Related]  

  • 24. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
    Li Q; Li W; Huang Y; Chen L
    J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staging liver fibrosis in chronic hepatitis B with T
    Yang L; Ding Y; Rao S; Chen C; Wu L; Sheng R; Fu C; Zeng M
    J Magn Reson Imaging; 2017 Apr; 45(4):1186-1194. PubMed ID: 27563840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Gamma-Glutamyl-Transpeptidase to Platelet Ratio Does not Show Advantages than APRI and Fib-4 in Diagnosing Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis B: A Retrospective Cohort Study in China.
    Li Q; Song J; Huang Y; Li X; Zhuo Q; Li W; Chen C; Lu C; Qi X; Chen L
    Medicine (Baltimore); 2016 Apr; 95(16):e3372. PubMed ID: 27100421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus.
    Imai H; Kamei H; Onishi Y; Ishizu Y; Ishigami M; Goto H; Ogura Y
    Transplant Proc; 2018 Jun; 50(5):1431-1436. PubMed ID: 29705278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Hu PJ; Bair MJ
    J Microbiol Immunol Infect; 2020 Aug; 53(4):542-549. PubMed ID: 31831303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
    Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
    Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
    [No Abstract]   [Full Text] [Related]  

  • 30. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?
    Sanvisens A; Muñoz A; Bolao F; Zuluaga P; Farré M; Jarrin I; Tor J; Muga R
    Drug Alcohol Depend; 2018 Jul; 188():180-186. PubMed ID: 29778771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
    Köksal İ; Yılmaz G; Parlak M; Demirdal T; Kınıklı S; Candan M; Kaya A; Akhan S; Aydoğdu Ö; Turgut H; Gürbüz Y; Dağlı Ö; Gökal AA; Güner R; Kuruüzüm Z; Tarakçı H; Beslen N; Erdoğan S; Özdener F; Study Group TCHC
    Turk J Gastroenterol; 2018 Jul; 29(4):464-472. PubMed ID: 30249562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of simple serum-based tests to exclude cirrhosis prior to hepatitis C treatment in non-hospital settings in Australia.
    Burrage L; Zimmerman H; Higgins S; Param K; Orme C; Mitchell J; O'Beirne J
    Intern Med J; 2021 Apr; 51(4):533-539. PubMed ID: 31994285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings.
    Liu K; Qin M; Tao K; Liang Z; Cai F; Zhao L; Peng P; Liu S; Zou J; Huang J
    J Clin Lab Anal; 2021 Feb; 35(2):e23640. PubMed ID: 33146916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study.
    Chen CL; Chang WC; Yi CH; Hung JS; Liu TT; Lei WY; Hsu CS
    J Formos Med Assoc; 2019 Feb; 118(2):628-635. PubMed ID: 30122312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in Chinese patients with chronic hepatitis B.
    Yue W; Li Y; Geng J; Wang P; Zhang L
    Medicine (Baltimore); 2019 Dec; 98(49):e18038. PubMed ID: 31804310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study.
    Jiménez-Sousa MA; Berenguer J; Fernández-Rodríguez A; Medrano LM; Aldámiz-Echevarria T; Pérez-Latorre L; Díez C; Martín-Vicente M; Gutiérrez-Rivas M; Martínez I; Resino S
    Infect Genet Evol; 2019 Jan; 67():112-120. PubMed ID: 30336268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis.
    Udompap P; Sukonrut K; Suvannarerg V; Pongpaibul A; Charatcharoenwitthaya P
    J Viral Hepat; 2020 Apr; 27(4):437-448. PubMed ID: 31799740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.
    Sonneveld MJ; Brouwer WP; Chan HL; Piratvisuth T; Jia JD; Zeuzem S; Liaw YF; Hansen BE; Choi H; Wat C; Pavlovic V; Gaggar A; Xie Q; Buti M; de Knegt RJ; Janssen HLA
    Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):538-544. PubMed ID: 30975477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
    Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS).
    Teshale E; Lu M; Rupp LB; Holmberg SD; Moorman AC; Spradling P; Vijayadeva V; Boscarino JA; Schmidt MA; Gordon SC;
    J Viral Hepat; 2014 Dec; 21(12):917-20. PubMed ID: 25131445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.